• Publications
  • Influence
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma
The pharmacokinetic and pharmacodynamic effects of inhaled corticosteroids (ICS) have shaped the efficacy and safety of these agents in the treatment of asthma. Important pharmacokinetic andExpand
  • 177
  • 13
  • PDF
Pharmacokinetics of [14C]Ciclesonide After Oral and Intravenous Administration to Healthy Subjects
BackgroundCiclesonide is a novel inhaled corticosteroid developed for the treatment of asthma.ObjectiveTo investigate the extent of oral absorption and bioavailability of ciclesonide referenced to anExpand
  • 100
  • 5
The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.
Ciclesonide (CIC) is an inhaled glucocorticosteroid. This study aimed to identify esterases involved in the metabolism of CIC to the active metabolite desisobutyryl-ciclesonide (des-CIC), and toExpand
  • 62
  • 4
Risk‐Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective
Inhaled glucocorticoids induce therapeutic and adverse systemic effects via the same types of receptors. Analysis of the pharmacokinetic/pharmacodynamic parameters of inhaled glucocorticoidsExpand
  • 82
  • 3
Protein Binding and Its Potential for Eliciting Minimal Systemic Side Effects with a Novel Inhaled Corticosteroid, Ciclesonide
Freely circulating, protein unbound, active inhaled corticosteroid (ICS) can cause systemic adverse effects. Desisobutyryl-ciclesonide (des-CIC) is the active metabolite of ciclesonide, an effective,Expand
  • 82
  • 3
Population Pharmacokinetics and Pharmacodynamics of Ciclesonide
Ciclesonide is a novel glucocorticoid that is converted into ciclesonide—active principle (CIC‐AP) in the lung. The study objectives were to identify a structural model for population pharmacokineticExpand
  • 100
  • 2
High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.
OBJECTIVE To examine the deposition and pharmacokinetics of ciclesonide administered via hydrofluoroalkane-metered dose inhaler (HFA-MDI) in patients with asthma. METHODS Twelve patients with mildExpand
  • 115
  • 2
Clinical Pharmacokinetic and Pharmacodynamic Profile of Inhaled Ciclesonide
  • R. Nave
  • Medicine
  • Clinical pharmacokinetics
  • 2009
Asthma is a chronic inflammatory disease of the airways, and inhaled corticosteroids (ICSs) are recommended as first-line therapy for persistent asthma of all severities. Ciclesonide is a novel ICS,Expand
  • 29
  • 2
Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar.
OBJECTIVE To evaluate whether the inflammatory process and bronchial constriction associated with asthma influence the pulmonary distribution and airway penetration of inhaled ciclesonide byExpand
  • 21
  • 2
Deposition and metabolism of inhaled ciclesonide in the human lung
Ciclesonide is an inhaled corticosteroid, administered as a prodrug via a metered-dose inhaler. Following deposition in the lung, ciclesonide is hydrolysed by esterases to form the pharmacologicallyExpand
  • 15
  • 2